- Home
- FUTU vs RLAY Comparison
FUTU vs RLAY Comparison
Compare FUTU & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUTU | RLAY |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 1.3B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FUTU | RLAY |
|---|---|---|
| Price | $170.27 | $8.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $208.60 | $16.00 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.17 | N/A |
| EPS | ★ 8.95 | N/A |
| Revenue | ★ $2,442,834,991.00 | $8,355,000.00 |
| Revenue This Year | $87.24 | $20.47 |
| Revenue Next Year | $13.85 | N/A |
| P/E Ratio | $19.31 | ★ N/A |
| Revenue Growth | ★ 87.15 | N/A |
| 52 Week Low | $70.60 | $1.78 |
| 52 Week High | $202.53 | $8.70 |
Technical Indicators
Market Signals| Indicator | FUTU | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 63.19 |
| Support Level | $166.60 | $7.42 |
| Resistance Level | $175.77 | $8.00 |
| Average True Range (ATR) | 5.39 | 0.52 |
| MACD | 0.59 | -0.00 |
| Stochastic Oscillator | 51.53 | 65.26 |
Price Performance
Historical ComparisonAbout FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).